Trial: 201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin
Expression Who Have Failed Standard Available Therapy



Principal Investigator

Ward, Jeffrey

Disease Site

Other Female Genital; Other Respiratory and Intrathoracic Organs; Ovary; Pancreas; Soft Tissue

Learn more about this study at: